Evidence map›Paper›PMID 37173731›Full record

ArticleBMC pulmonary medicine2023

Butyrate inhibits iILC2-mediated lung inflammation via lung-gut axis in chronic obstructive pulmonary disease (COPD).

Min Jiang, Zhiwei Li, Fengbo Zhang, Zheng Li, Dan Xu, Jing Jing, Fengsen Li, Jing Wang, Jianbing Ding

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Air pollution-induced airway epithelial barrier dysfunction in COPD: a narrative review of mechanisms and therapeutic implications.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. [Therapeutic effects of natural products on animal models of chronic obstructive pulmonary disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Min Jiang *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
Zhiwei Li *Clinical Laboratory Center, People's Hospital of Xinjiang Uygur Autonomous, Urumqi, 830001, Xinjiang, China.
Fengbo ZhangDepartment of Clinical Laboratory, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang, China.
Zheng LiXinjiang Key Laboratory of Respiratory Disease Research, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, No. 116, Huanghe Road, Urumqi, 830011, Xinjiang, China.
Dan XuXinjiang Key Laboratory of Respiratory Disease Research, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, No. 116, Huanghe Road, Urumqi, 830011, Xinjiang, China.
Jing JingXinjiang Key Laboratory of Respiratory Disease Research, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, No. 116, Huanghe Road, Urumqi, 830011, Xinjiang, China.
Fengsen LiXinjiang Key Laboratory of Respiratory Disease Research, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, No. 116, Huanghe Road, Urumqi, 830011, Xinjiang, China.
Jing WangXinjiang Key Laboratory of Respiratory Disease Research, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, No. 116, Huanghe Road, Urumqi, 830011, Xinjiang, China. jingw_xj@163.com.
Jianbing DingDepartment of Immunology, College of Basic Medicine, Xinjiang Medical University, No. 4, Xinyi Road, Urumqi, 830011, Xinjiang, China. 1601379937@qq.com.
Xinjiang Medical University · CNXinjiang Uygur Autonomous Region Uygur Medicine Hospital · CNPeople's Hospital of Xinjiang Uygur Autonomous Region · CN

Funding

the China Postdoctoral Science Foundation 2021MD703892the National Natural Science Foundation Regional Fund Project 81760793the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund Grant SKL-HIDCA-2019-ZY15
6 · The paper itself

Abstract

backgroundThe study investigated the effects and underlying mechanisms of intestinal flora metabolite butyrate on inflammatory ILC2 cells (iILC2s)-mediated lung inflammation in chronic obstructive pulmonary disease (COPD).

methodsMouse models of COPD and acute exacerbation of COPD (AECOPD) were established. Flow cytometry was used to detect natural ILC2 cells (nILC2s) and iILC2s in lung and colon tissues. The 16s rRNA and GC-MS were used to detect microbial flora and short chain fatty acids (SCFAs) in feces. ELISA was used to detect IL-13 and IL-4. Western blot and qRT-PCR were used to detect the relative protein and mRNA levels, respectively. In vitro experiments were performed with sorted ILC2s from colon tissues of control mice. Mice with AECOPD were treated with butyrate.

resultsThe nILC2s and iILC2s in lung and colon tissues of AECOPD mice were significantly higher than control groups. The abundance of the flora Clostridiaceae was significantly reduced, and the content of SCFAs, including acetate and butyrate, was significantly reduced. The in vitro experiments showed that butyrate inhibited iILC2 cell phenotype and cytokine secretion. Butyrate treatment reduced the proportion of iILC2 cells in the colon and lung tissues of mice with AECOPD.

conclusionsThe nILC2s and iILC2s in the colon tissues are involved in the course of COPD. Decreased Clostridiaceae and butyrate in AECOPD mice caused the accumulation of iILC2 cells in the intestines and lungs. Supplementation of butyrate can reduce iILC2 in the intestine and lung tissues. Our data may provide new ideas for prevention and treatment of COPD.

Indexed as

PneumoniaPulmonary Disease, Chronic ObstructiveAnimalsButyratesImmunity, InnateLungLymphocytesMiceRNA, Ribosomal, 16SButyratesRNA, Ribosomal, 16SAcute exacerbation of COPD (AECOPD)ButyrateChronic obstructive pulmonary disease (COPD)Inflammatory ILC2sShort chain fatty acids (SCFAs)

Identifiers

PMID37173731
PMCPMC10182695
OpenAlexW4376275026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.